Medicines360 Appoints Rolf Jansen as Vice President of Drug Development and Manufacturing

Jansen to Lead Product Expansion Focused on Essential Medicines Facing Access Challenges 

SAN FRANCISCO – July 17, 2020 Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Drug Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty years of pharmaceutical experience developing and producing successful products in the U.S. at companies including Relypsa, KindredBio, Johnson & Johnson and ALZA. In this new role, Jansen will lead the organization’s development of medicines focused on essential women’s health products that are facing drug shortages or have high prices impacting availability.

“At a time when other pharmaceutical companies are decreasing investments in women’s health research and development, I am thrilled to join an organization that is bringing affordable medicines to market,” said Jansen. We at Medicines360 know that too many women face access barriers to well established, safe and effective medicines that are essential to their health. As a nonprofit pharmaceutical organization, we are determined to find and solve problems that matter most to women.”

As Vice President, Jansen will be responsible for managing and implementing Medicines360’s manufacturing and development strategy. This will include the full breadth of chemical sciences, engineering, manufacturing, analytical technologies, logistics and quality control.

 “COVID-19 has exacerbated the challenges women face when trying to access the healthcare and medicines they need. Rolf’s expertise will ensure that Medicines360 can continue expanding our portfolio with a focus on affordability and strengthening product supply for critical medicines that serve women,” said Jessica Grossman, M.D., CEO of Medicines360. “Mr. Jansen will further support our goal to lower the cost of high-quality medicines and stabilize the drug supply of health products for women, regardless of whether they are branded or generic.”

Since its founding in 2009, Medicines360 has brought a new product to market, formed partnerships in the U.S. and globally, and designed affordable and sustainable pricing strategies. With the addition of Jansen’s role, the organization will continue to seek new ways to advance global, equitable access to women’s health products. Medicines360 will build on its expertise in clinical trials, regulatory approvals, and customer engagement with U.S. safety-net clinics and with service delivery partners in low- and middle-income countries.

“As the first U.S.-based nonprofit pharmaceutical organization with a drug developed and marketed to overcome affordability and availability barriers, Medicines360 is uniquely suited to develop accessible and high-quality generic drugs that are essential to women’s healthcare,” said Lisa David, CEO of Public Health Solutions and a Board Member of Medicines360. “In addition, Medicines360 has a history of conducting robust clinical trials on its products, with the largest ongoing phase three clinical trial in the country for its first product, a hormonal intrauterine system (IUS).”

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical company with a mission to remove cost as a barrier to health by developing and providing affordable Women’s Health products. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit www.medicines360.org

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical organization with a mission to catalyze equitable access to medicines and devices through product development, policy advocacy, and collaboration with global and US partners. Medicines360, through its subsidiary Impact RH360, launched the Avibela Project to expand access to hormonal IUDs in low- and middle-income countries. For more information, visit medicines360.org

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.